(Cancer of Unknown Primary) Is Opdivo Effective?
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
- December 13, 2021
- 1 min read
On November 26, 2021, Dr. Junko Tanizaki and colleagues from Kindai University Faculty of Medicine published results in Annals of Oncology from the NivoCUP Phase 2 clinical trial evaluating the efficacy and safety of the anti-PD-1 antibody Opdivo (nivolumab) in cancer of unknown primary (CUP) patients.
This multi-center, single-arm Phase 2 trial administered Opdivo (240 mg every 2 weeks, up to 52 cycles) to CUP patients (N=56), with objective response rate (ORR) as the primary endpoint. Of these patients, 45 had received one prior line of therapy.
The trial was initiated because CUP carries a poor prognosis, and immune checkpoint inhibitors have demonstrated efficacy across multiple cancer types. The study aimed to evaluate the therapeutic value of nivolumab in this difficult-to-treat population.
Results (in patients with prior treatment, N=45):
- Objective response rate (ORR): 22.2%
- Median progression-free survival (PFS): 4.0 months
- Median overall survival (OS): 15.9 months
Safety: The safety profile was consistent with existing nivolumab clinical trial data. No treatment-related deaths were reported.
Conclusion: Based on the NivoCUP trial results, Dr. Tanizaki and colleagues concluded that Opdivo demonstrated promising anti-tumor activity in CUP patients, potentially representing a new treatment option for this population.
Source: https://www.annalsofoncology.org/article/S0923-7534(21)04824-9/fulltext
-
Immunotherapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4